---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-217822"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:14:57.861150+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended

## Summary
- REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.
- All secondary endpoints (MFI, shoulder strength, PROs) did not reach statistical significance.
- Fulcrum suspends losmapimod development; safety profile consistent with prior studies.
- $273.8M cash as of June 30 used for pociredir (SCD), DBA programs, and early discovery.

## SEC filing metadata
- accession: 0001193125-24-217822
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312524217822/0001193125-24-217822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312524217822/d844807d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-217822
- JSON: https://secwatch.observer/filing/0001193125-24-217822.json
- Plain text: https://secwatch.observer/filing/0001193125-24-217822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.